• Leveljump Healthcare has acquired an additional 10.44 per cent of Real Time Medical Inc.
  • Leveljump has agreed to pay the vendor 7127651 Canada Inc. a cash payment of $579,918 and 2,557,590 common shares of Leveljump
  • Upon closing of the purchase agreement, Leveljump will own a 35.99 per cent interest in Real Time Medical Inc.
  • Leveljump Healthcare is a Canadian leader in business-to-business (B2B) telehealth solutions
  • LevelJump Healthcare Corp. (TSXV:JUMP) is unchanged on the day, trading at C$0.14 per share at 1:00 pm ET

Leveljump Healthcare has acquired an additional 10.44 per cent of Real Time Medical Inc.

Under the terms of the agreement, Leveljump has agreed to acquire all of the outstanding shares of 7127651 Canada Inc. (712), a private Nova Scotia-based federal corporation. 712 holds 1,784,364 common shares of Real Time Medical Inc.

Leveljump has agreed to pay the vendor $963,556.56, including a cash payment of $579,918 payable in 3 instalments over four months and 2,557,590 common shares. 

Leveljump has also agreed to purchase a promissory note of Real Time Medical in the principal amount of $50,000 with any accrued interest.

Upon closing of the purchase agreement, Leveljump will own a 35.99 per cent interest in RTM.

Leveljump Healthcare Corp. is a Canadian leader in business-to-business (B2B) telehealth solutions.

LevelJump Healthcare Corp. (TSXV:JUMP) is unchanged on the day, trading at C$0.14 per share at 1:00 pm ET.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.